Drug Trial Radar · NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Last checked: Nov 19, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
737
Planned (sponsor's estimate)
Start
Jul 22, 2022
Primary completion
Oct 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Loxo Oncology, Inc.Eli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Feb 24, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment for their cancer. The purpose of Part 2 of this study evaluates pirtobrutinib monotherapy in treatment-naïve participants with CLL/SLL with 17p deletions. Participation could last up to six years for Part 1. Participation could last up to 2 years for Part 2.
Conditions
- Chronic Lymphocytic Leukemia
- Leukemia, Lymphocytic
- Leukemia, B-cell
- Small Lymphocytic Lymphoma
Interventions
PirtobrutinibDrug
Administered orally.
IbrutinibDrug
Administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (Cri), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 1Time frame: Baseline to best overall response the best response recorded from Cycle 1 Day 1 until data cutoff date, PD, or start of new anticancer treatment, whichever is the earliest] (approximately 3 years and 5 months)
- Percentage of Participants Achieving Complete Response (CR), Complete Remission with Incomplete Hematologic Recovery (CRi), Nodular Partial Remission (nPR) or Partial Response (PR): Overall Response Rate (ORR) Part 2Time frame: Baseline to best overall response the best response recorded from Cycle 1 Day 1 until data cutoff date, PD, or start of new anticancer treatment, whichever is the earliest (Approximately 2 years and 3 months)
Locations
143 sites in 23 countries. Site status is shown where the registry gives one.
Pacific Cancer Medical Center, Inc
Anaheim, California · Recruiting
TOI Clinical Research
Cerritos, California · Recruiting
Stanford School of Medicine-Cancer Clinical Trials Office
Palo Alto, California · Recruiting
California Cancer Associates for Research and Excellence
San Marcos, California · Active not recruiting
Florida Cancer Specialists
Fort Myers, Florida · Recruiting
Cancer Specialists of North Florida -St Augustine
Saint Augustine, Florida · Recruiting
Florida Cancer Specialists East
West Palm Beach, Florida · Recruiting
Hematology Oncology Clinic
Baton Rouge, Louisiana · Active not recruiting
Tulane Cancer Center Office of Clinical Research
New Orleans, Louisiana · Active not recruiting
American Oncology Partners of Maryland, PA
Bethesda, Maryland · Recruiting
St. Vincent Frontier Cancer Center
Billings, Montana · Recruiting
Cancer Care Associates Of York
York, Pennsylvania · Active not recruiting
Prisma Health Cancer Institute
Greenville, South Carolina · Active not recruiting
Sarah Cannon Research Institute SCRI
Nashville, Tennessee · Recruiting
Kelsey Research Foundation
Houston, Texas · Active not recruiting
Lumi Research
Kingwood, Texas · Recruiting
Virginia Cancer Institute
Richmond, Virginia · Recruiting
Medical Oncology Associates, PS
Spokane, Washington · Recruiting
MultiCare Health System Institute for Research and Innovation
Spokane, Washington · Active not recruiting
Alexander Fleming
Ciudad Autónoma de Buenos Aire, Argentina · Recruiting
Hospital Privado De Comunidad
Mar del Plata, Argentina · Active not recruiting
Clínica de Nefrología, Urología y Enfermedades Cardiovasculares
Santa Fe, Argentina · Recruiting
One Clinical Research
Nedlands, Australia · Active not recruiting
Western Health, Sunshine Hospital
St Albans, Australia · Active not recruiting
The Perth Blood Institute
West Perth, Australia · Recruiting
Hanusch Krankenhaus
Vienna, Austria · Active not recruiting
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
Leuven, Belgium · Recruiting
VITAZ
Sint-Niklaas, Belgium · Recruiting
Fundação Pio XII - Hospital de Câncer de Barretos
Barretos, Brazil · Recruiting
Upeclin - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - UNESP
Botucatu, Brazil · Recruiting
Hemocentro Unicamp
Campinas, Brazil · Recruiting
Hospital Uopeccan - Centro de Pesquisa Clinica
Cascavel, Brazil · Recruiting
Centro Integrado de Oncologia de Curitiba
Curitiba, Brazil · Active not recruiting
Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer
Curitiba, Brazil · Recruiting
Instituto do Câncer - Hospital São Vicente de Paulo
Passo Fundo, Brazil · Recruiting
Centro Gaucho Integrado - Mae de Deus Center
Porto Alegre, Brazil · Recruiting
Hospital de Clínicas de Ribeirão Preto
Ribeirão Preto, Brazil · Recruiting
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia
Santo André, Brazil · Recruiting
Centro Integrado de Pesquisa Clinica
São José do Rio Preto, Brazil · Recruiting
Hospital BP
São Paulo, Brazil · Recruiting
Showing 40 of 143 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.